During the corresponding time, Adaptive Biotechnologies Corporation recorded a revenue increase by 21.53 % year on year, sequentially revenue grew by 0.96 %. While revenue at the Adaptive Biotechnologies Corporation's corporate clients
Adaptive Biotechnologies's Comment on Sales, Marketing and Customers
The company serves two primary customer segments: clinicians and biopharmaceutical companies. Clinicians utilize the clonoSEQ clinical diagnostic testing services to guide treatment decisions based on minimal residual disease (MRD) status. Biopharmaceutical companies collaborate with the company to support drug development by employing the clonoSEQ assay in clinical trials. Notable studies include the Phase 3 MIDAS study involving transplant-eligible multiple myeloma patients, the Phase 2 EndRAD study with children and young adults diagnosed with B-cell acute lymphoblastic leukemia (B-ALL), and the Phase 3 MajesTEC-3 study focusing on patients with relapsed/refractory multiple myeloma (RRMM). These studies highlight the application of clonoSEQ in informing treatment decisions and advancing novel therapies.
News about Adaptive Biotechnologies Corporation Contracts
Adaptive Biotechnologies has achieved a significant milestone with the announcement that its clonoSEQ® technology has become the first in vitro diagnostic regulation (IVDR) certified assay in the European Union (EU) for detecting minimal residual disease (MRD) in patients with lymphoid malignancies. This groundbreaking certification is set to revolutionize the clinical management of conditions such as multiple myeloma, chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL), by offering unprecedented accuracy in disease monitoring and prognosis.Understanding and monitoring MRD is crucial for the effective treatment of lymphoid malignancies. MRD refers to the small number of cancer cells t...
Adaptive Biotechnologies’s Comment on Sales, Marketing and Customers
The company serves two primary customer segments: clinicians and biopharmaceutical companies. Clinicians utilize the clonoSEQ clinical diagnostic testing services to guide treatment decisions based on minimal residual disease (MRD) status. Biopharmaceutical companies collaborate with the company to support drug development by employing the clonoSEQ assay in clinical trials. Notable studies include the Phase 3 MIDAS study involving transplant-eligible multiple myeloma patients, the Phase 2 EndRAD study with children and young adults diagnosed with B-cell acute lymphoblastic leukemia (B-ALL), and the Phase 3 MajesTEC-3 study focusing on patients with relapsed/refractory multiple myeloma (RRMM). These studies highlight the application of clonoSEQ in informing treatment decisions and advancing novel therapies.
Sources:
Adaptive Biotechnologies Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Adaptive Biotechnologies Corporation’s corporate clients.
For your research, we’ve provided 9 tables on Adaptive Biotechnologies Corporation corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
173.66 %